These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38542276)

  • 1. Differential Gene Regulatory Network Analysis between Azacitidine-Sensitive and -Resistant Cell Lines.
    Park H; Miyano S
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unveiling Gene Regulatory Networks That Characterize Difference of Molecular Interplays Between Gastric Cancer Drug Sensitive and Resistance Cell Lines.
    Park H
    J Comput Biol; 2024 Mar; 31(3):257-274. PubMed ID: 38394313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Expression Profile of Patients with Acute Myeloid Leukemia in Response to Azacitidine with Biological System Approach.
    Hejab R; Rahimi H; Abedinlou H; Ghoraeian P
    Microrna; 2023; 12(3):233-242. PubMed ID: 37642007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.
    Hur EH; Jung SH; Goo BK; Moon J; Choi Y; Choi DR; Chung YJ; Lee JH
    Oncotarget; 2017 Feb; 8(7):11748-11762. PubMed ID: 28052028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines.
    Kutyna MM; Loone S; Saunders VA; White DL; Kok CH; Hiwase DK
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
    Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
    Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sparse spectral graph analysis and its application to gastric cancer drug resistance-specific molecular interplays identification.
    Park H; Miyano S
    PLoS One; 2024; 19(7):e0305386. PubMed ID: 38968283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia.
    Wang A; Fang M; Jiang H; Wang D; Zhang X; Tang B; Zhu X; Hu W; Liu X
    Biomed Pharmacother; 2022 Sep; 153():113527. PubMed ID: 36076608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
    Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
    BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of DNA demethylation on the upregulation of the NRN1 and TNFAIP3 genes associated with advanced gastric cancer.
    Wisnieski F; Santos LC; Calcagno DQ; Geraldis JC; Gigek CO; Anauate AC; Chen ES; Rasmussen LT; Payão SLM; Artigiani R; Demachki S; Assumpção PP; Lourenço LG; Arasaki CH; Pabinger S; Krainer J; Leal MF; Burbano RR; Arruda Cardoso Smith M
    J Mol Med (Berl); 2020 May; 98(5):707-717. PubMed ID: 32285140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
    Thépot S; Lainey E; Cluzeau T; Sébert M; Leroy C; Adès L; Tailler M; Galluzzi L; Baran-Marszak F; Roudot H; Eclache V; Gardin C; de Botton S; Auberger P; Fenaux P; Kroemer G; Boehrer S
    Cell Cycle; 2011 Jul; 10(14):2323-30. PubMed ID: 21654193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
    Pettigrew KA; Armstrong RN; Colyer HA; Zhang SD; Rea IM; Jones RE; Baird DM; Mills KI
    Genes Chromosomes Cancer; 2012 Aug; 51(8):768-80. PubMed ID: 22517724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia.
    Weidenauer K; Schmidt C; Rohde C; Pauli C; Blank MF; Heid D; Waclawiczek A; Corbacioglu A; Göllner S; Lotze M; Vierbaum L; Renders S; Krijgsveld J; Raffel S; Sauer T; Trumpp A; Pabst C; Müller-Tidow C; Janssen M
    Leukemia; 2023 Aug; 37(8):1611-1625. PubMed ID: 37414921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.
    Carter JL; Su Y; Qiao X; Zhao J; Wang G; Howard M; Edwards H; Bao X; Li J; Hüttemann M; Yang J; Taub JW; Ge Y
    Biochem Pharmacol; 2023 Oct; 216():115759. PubMed ID: 37604291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive information-based differential gene regulatory networks analysis (CIdrgn): Application to gastric cancer and chemotherapy-responsive gene network identification.
    Park H; Imoto S; Miyano S
    PLoS One; 2023; 18(8):e0286044. PubMed ID: 37610997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncovering Molecular Mechanisms of Drug Resistance via Network-Constrained Common Structure Identification.
    Park H; Yamaguchi R; Imoto S; Miyano S
    J Comput Biol; 2022 Mar; 29(3):257-275. PubMed ID: 35073162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemic stem cells and therapy resistance in acute myeloid leukemia.
    Stelmach P; Trumpp A
    Haematologica; 2023 Feb; 108(2):353-366. PubMed ID: 36722405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.
    Solly F; Koering C; Mohamed AM; Maucort-Boulch D; Robert G; Auberger P; Flandrin-Gresta P; Adès L; Fenaux P; Kosmider O; Tavernier-Tardy E; Cornillon J; Guyotat D; Campos L; Mortreux F; Wattel E
    Clin Cancer Res; 2017 Jun; 23(12):3025-3034. PubMed ID: 27881579
    [No Abstract]   [Full Text] [Related]  

  • 20. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.